(Q24244317)

2 July 2019

review article

1 reference

title

Vaccines for preventing malaria (pre-erythrocytic) (English)

1 reference

2 July 2019

0 references

1 reference

1 reference

2

0 references

Patricia M. Graves

object named as

Patricia M Graves

series ordinal

1

0 references

language of work or name

English

0 references

publication date

18 October 2006

1 reference

2 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

2 July 2019

issue

4

1 reference

2 July 2019

page(s)

CD006198

1 reference

2 July 2019

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

A malaria vaccine based on a sporozoite antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Vaccines for preventing malaria (SPf66)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Vaccines for preventing malaria (blood-stage)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

The global distribution and population at risk of malaria: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

Progress and challenges for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

The global distribution of clinical episodes of Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006198

A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.

21 January 2018

1 reference

12 December 2020

Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studies

1 reference

12 December 2020

Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific

1 reference

12 December 2020

Malaria vaccine developments

1 reference

12 December 2020

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

1 reference

12 December 2020

Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk?

1 reference

12 December 2020

Update on the clinical development of candidate malaria vaccines.

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A

1 reference

12 December 2020

Safety and Immunogenicity of a Plasmodium vivax Sporozoite Vaccine

1 reference

12 December 2020

Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso)

1 reference

12 December 2020

Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant

1 reference

12 December 2020

10.1002/14651858.CD006198

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6532586

1 reference

2 July 2019

PubMed publication ID

17054280

1 reference

2 July 2019